Wuhan Hvsen Biotechnology Co Ltd Working Capital to Net Assets Ratio
Wuhan Hvsen Biotechnology Co Ltd working capital to net assets ratio. Wuhan Hvsen Biotechnology Co Ltd (300871) has a Working Capital to Net Assets ratio of 33.9% as of June 2026. Working capital of CN¥788.31 Million (current assets of CN¥1.54 Billion minus current liabilities of CN¥753.65 Million) is measured against net assets of CN¥2.33 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of Wuhan Hvsen Biotechnology Co Ltd to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Wuhan Hvsen Biotechnology Co Ltd (2016–2025)
Working capital to net assets ratio of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2025. This chart shows how Wuhan Hvsen Biotechnology Co Ltd's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of June 2026, the ratio stands at 33.9%, reflecting working capital of CN¥788.31 Million against net assets of CN¥2.33 Billion CNY. See Wuhan Hvsen Biotechnology Co Ltd (300871) liquidity interval to measure how many days the company can operate on defensive assets alone.
Wuhan Hvsen Biotechnology Co Ltd Working Capital to Net Assets Ratio by Year (2016–2025)
Wuhan Hvsen Biotechnology Co Ltd working capital to net assets ratio by year from 2016 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 300871 asset base.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 25.9% | CN¥566.60 Million | CN¥2.19 Billion | CN¥1.31 Billion | CN¥740.33 Million | ▼ -0.7 pp |
| 2024 | 26.6% | CN¥389.27 Million | CN¥1.47 Billion | CN¥1.31 Billion | CN¥923.32 Million | ▼ -5.6 pp |
| 2023 | 32.1% | CN¥484.90 Million | CN¥1.51 Billion | CN¥1.27 Billion | CN¥781.08 Million | ▼ -3.3 pp |
| 2022 | 35.5% | CN¥546.55 Million | CN¥1.54 Billion | CN¥1.35 Billion | CN¥804.93 Million | ▼ -32.2 pp |
| 2021 | 67.7% | CN¥1.10 Billion | CN¥1.62 Billion | CN¥1.60 Billion | CN¥503.27 Million | ▲ +6.9 pp |
| 2020 | 60.8% | CN¥838.48 Million | CN¥1.38 Billion | CN¥1.18 Billion | CN¥338.67 Million | ▲ +37.3 pp |
| 2019 | 23.5% | CN¥88.78 Million | CN¥378.28 Million | CN¥292.54 Million | CN¥203.77 Million | ▼ -18.7 pp |
| 2018 | 42.2% | CN¥136.83 Million | CN¥324.52 Million | CN¥275.75 Million | CN¥138.92 Million | ▲ +15.4 pp |
| 2017 | 26.7% | CN¥59.62 Million | CN¥223.11 Million | CN¥177.70 Million | CN¥118.08 Million | ▲ +1.8 pp |
| 2016 | 24.9% | CN¥38.58 Million | CN¥154.70 Million | CN¥136.58 Million | CN¥98.00 Million | — |